Neutrophil-Lymphocyte Ratio in Patients with Acute Heart Failure Predicts In-Hospital and Long-Term Mortality

Abstract

The application of a simple blood test to predict prognosis in acute heart failure (AHF) patients is not well established. Neutrophil-lymphocyte ratio (NLR) is inexpensive and easy to obtain in hospitalized patients using a routine blood test. We evaluate the prognostic implications of NLR as an independent predictor of in-hospital and long-term mortality in AHF patients. Among 5625 patients enrolled in the Korean Acute Heart Failure registry, 5580 patients were classified into quartiles by their NLR level, and analyzed for in-hospital and post-discharge three-year mortality. Patients in the highest NLR quartile had the highest in-hospital and post-discharge three-year mortality. The same results were seen by dividing the aggravating factor into the infection or ischemia group and the non-infection or non-ischemia group. For patients aggravated from infection or ischemia, a cut-off NLR value was 7.0 that increase the risk of in-hospital and post-discharge three-year mortality. In subgroups of patients not aggravated from infection or ischemia, a cut-off NLR value was 5.0 that increase the risk of in-hospital and post discharge three-year mortality. Elevated NLR in AHF patients at the index hospitalization is an independent predictor for in-hospital and post-discharge three-year mortality. Taken together, NLR is a marker for risk assessment of AHF patients.

1. Introduction

Inflammation plays a crucial role in the pathogenesis and progression of cardiovascular disease. Numerous inflammatory biomarkers are correlated with disease severity and prognosis across throughout heart failure (HF) [1]. White blood cell (WBC) count and its subtypes are classical markers of inflammation in cardiovascular disease [2]. Leukocytosis increases incidence of HF hospitalization and mortality [3]. Moreover, neutrophilia is associated with increased incidence of acute decompensated heart failure in patients with acute myocardial infarction [4], and lymphopenia is related to poor prognosis in patients with HF [5,6].

Neutrophil-lymphocyte ratio (NLR), which neutrophils counts are divided by lymphocyte counts, is used as a new additional inflammatory markers [7]. Elevated NLR was recently reported to be an independent predictor of both all-cause mortality and cardiovascular disease [8,9]. Previous studies showed that NLR is related to increased mortality or heart transplantation risk in patients with chronic HF [10,11], but these studies are limited by single-center study design and relatively small sample size. Therefore, we aimed to evaluate the prognostic implications of NLR on in-hospital and post-discharge three-year mortality in patients with AHF.

2. Materials and Methods

2.1. Study Design and Data Collection

The KorAHF (Korean Acute Heart Failure) registry is a prospective, nationwide multicenter cohort that consecutively enrolled 5625 patients hospitalized for acute HF syndrome from 10 tertiary care hospitals throughout the country from March 2011 to February 2014. Detailed information on the study design and results or the KorAHF registry has been previously published elsewhere [12,13]. In brief, patients who had signs or symptoms of acute HF such as either pulmonary edema, objective findings of left ventricular systolic dysfunction, or structural heart disease were enrolled in the study and there were no other specific exclusion criteria. At index admission, information about patient demographics, medical history, symptoms and signs of HF, laboratory test results, electrocardiogram and echocardiography, current medication, hospital course, and clinical outcomes were collected. In February 2017, the three-years follow-up of all enrolled patients were completed. During the follow-up (at one month, three months, six months, one year, and annually thereafter), information about clinical outcomes, laboratory data, and medication has been collected. The study was conducted in accordance with the declaration of Helsinki, and written informed consent was obtained before enrollment. All study protocol were reviewed and approved by the Institutional Review Board of each participating hospital (H-1102-072-352) in February 2011 and also registered with ClinicalTrials.gov (NCT01389843).

2.2. Study Endpoints and Definitions

The main clinical outcomes of the study were adverse in-hospital outcomes (defined as all-cause mortality or urgent heart transplantation during hospitalization) and all-cause mortality during the minimum three-year follow-up after discharge. In-hospital mortality and cause of death were adjudicated by an independent event committee. Each category of death have been presented in previous publication [14]. This adjudication form was made with reference by the adjudication of death of typical 3-phase randomized control trials such as RELAX and RELAX-AHF-2 trial [15,16]. The mortality data for patients who were lost to follow-up were collected from the National Insurance database or National Death Records of Korea.

NLR was calculated that neutrophils counts are divided by lymphocyte counts, using the same blood samples drawn at admission. Participants were classified into quartiles by their NLR level.

Left ventricular ejection fraction (LVEF) values were measured using thansthoracic echocardiography performed during the index hospitalization. Quantitative calculation using the modified Simpson’s biplane method was recommended for LVEF measurement, but visually estimated LVEF, measured by echo-specialized cardiologists, was also accepted as valid for HF categorization. According to the 2016 European Society of Cardiology (ESC) HF guidelines, heart failure with preserved ejection fraction (HFpEF) was defined as LVEF ≥ 50% and heart failure with reduced ejection fraction (HFrEF) was defined as LVEF < 40%. Patients with LVEF between 40 and 49% were considered to have heart failure with midrange ejection fraction (HFmrEF) [17].

To evaluate the association between NLR quartiles and in-hospital and post-discharge three-year mortality by aggravating factor, the patients were divided into two groups according to the aggravating factor (patients whose aggravating factor was infection or ischemia, and patients whose aggravating factor was not infection or ischemia).

2.3. Statistical Analyses

Continuous variables are expressed as mean ± standard deviation and analyzed using the Student’ test, one-way ANOVA test or Kruskal–Wallis test. Categorical variables are presented as numbers and relative frequencies (percentages) and were compared with the Chi-square test. Cox proportional hazard regression model was used to identify the predictors associated with the NLR quartiles with in-hospital and post-discharge three-year mortality. Variables that were statistically significant in the univariate analysis were included in the multivariable model, except variables that had >10% missing values or that were closely related to other clinical variables. Post-discharge survival was assessed using Kaplan–Meier estimate, and the association between NLR quartiles and crude all-cause death was compared using Log-rank test. To find the cut-off value of the NLR, the multivariate restricted cubic splines methods was used. This method provide a useful tool for the analysis of the effect of a continuous predictor on an outcome when the relationship between an outcome (dependent) variable and the explanatory (indepednet) variables is not linear because this method allows for great flexibility in the form of the relationship between predictor and outcome [18,19]. All p values are two-sided, and a value of less than 0.05 was considered statistically significant. All data were analyzed using SPSS v25.0 (IBM Corporation, Armonk, NY, USA).

3. Results

Of the 5625 patients enrolled in the KorAHF registry, 45 patients were excluded because their total and differential WBC counts were not available (n = 24), or they were not identified whether they survived or died during the follow-up period (n = 21). The final study participants consisted of 5580 (99.2%) patients (Scheme 1). The baseline characteristics of the study population according to NLR quartile are listed in Table 1. Patients in the higher NLR quartile were older and had lower BMI and more history of hypertension, diabetes, ischemic heart disease, and cerebrovascular disease. These patients also demonstrated higher heart rates and increased incidence of New York Heart Association class III or IV. Laboratory findings presented that patients in the higher NLR quartile were associated with increased WBC counts, blood urea nitrogen, and serum creatinine, and decreased hemoglobin, albumin, and sodium levels. These patients had higher incidence of B-type natriuretic peptide (BNP) ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL.

3.1. In-Hospital Mortality and 3-Year Survival After Discharge

In-hospital mortality including urgent heart transplantation occurred in 331 (5.9%) of the cases during admission. Patients in the highest NLR quartile had a higher rate of in-hospital mortality (9.9%, n = 138) compared with those in any other three quartiles. Patients belonging to NLR quartile 4 had a longer duration of hospital stay and higher rate of intensive care unit/coronary care unit admission. The details of in-hospital clinical outcomes are shown in Supplementary Table S1.

Of the initial 5580 patients who were hospitalized with AHF, 5,312 patients (95.2%) survived to discharge. A total of 11 subjects were lost to follow-up, and the three-year follow-up rate after discharge was 99.8%. Overall, 1891 patients (35.7%) died during the three-year follow-up period. Figure 1 presents overall in-hospital mortality and three-year survival after discharge according to the NLR quartiles. As compared with quartile 1, overall in-hospital mortality and post-discharge three-year mortality were increasing in quartiles 2, 3, and 4 (p < 0.001, p < 0.001, respectively). Even at post-discharge one month and six months, the overall survival of four groups according to quartile showed a significant difference. In univariate and multivariate analyses and Cox regression analysis with NLR quartile 1 as the reference, the patients in NLR quartile 4 showed higher overall in-hospital mortality (adjusted odds ratio (OR) 2.23, 95% confidence interval (CI) 1.44–3.44) and post-discharge three-year mortality (adjusted OR 1.44, 95% CI 1.24–1.67) (Table 2, Supplementary Table S6).

The subgroup analysis included the evaluation of the association between NLR quartiles and in-hospital and post-discharge three-year mortality in patients classified according to the frequency of HF and to the severity of left ventricular systolic function (LVEF) (Supplementary Figures S1 and S2). Regardless of the number of exacerbations of HF and the severity of LVEF, the higher the NLR, the worse the overall in-hospital survival and post-discharge three-year survival. In the patients of HFpEF, OR tends to increase from Quartile 3. In-hospital and post-discharge three-year mortality in Quartile 4 are 1.83 (95% CI, 0.60–5.56), 1.81 (95% CI, 1.34–2.42), respectively (Supplementary Table S3).

3.2. Relationship between NLR and Overall Survival According to the Aggravating Factor of HF

Subgroup analysis was performed by dividing the aggravating factor of HF into two groups [non-ischemia/non-infection group and ischemia/infection group] (Figure 2). In the non-ischemia/non-infection group, the baseline characteristics of the population according to NLR quartile are listed in Table 3. Patients in the higher NLR quartile were older and had lower BMI and more history of hypertension, diabetes, ischemic heart disease, and prior admission due to HF. Patients in the higher NLR quartile demonstrated higher heart rates and increased incidence of New York Heart Association class III or IV. Laboratory findings presented that patients in the higher NLR quartile were associated with increased WBC counts, blood urea nitrogen, and serum creatinine, and decreased hemoglobin, albumin, and sodium levels. These patients had higher incidence of BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL and renal replacement therapy. In quartile 4, 65 patients (8.3%) died and showed the highest in-hospital mortality. As shown in Figure 1, the higher the NLR quartile, the lower the overall in-hospital survival and post-discharge three-year survival. In multivariate analysis, as compared with NLR quartile 1, the adjusted ORs of in-hospital mortality and post-discharge three-year mortality in quartile 4 were 2.39 (95% CI, 1.19–4.81) and 1.81 (95% CI, 1.40–2.35), respectively (Table 4A).

The trends of the baseline characteristics of the ischemia/infection group are similar to that of the non-ischemia/non-infection group (Table 5). Of the 613 patients in quartile 4, 69 patients (11.3%) died, with the highest rate among the 4 quartiles. Multivariate analysis showed that NLR quartile 4 showed a higher in-hospital mortality (adjusted OR 2.24, 95% CI 1.26–4.00) and post-discharge three-year mortality (adjusted OR 1.30, 95% CI 1.05–1.73) with NLR quartile 1 as the reference (Table 4B). The survival curves showed consistent results, as shown in Figure 2.

3.3. Cut-Off Value of NLR

The cut-off value of the overall in-hospital mortality and post-discharge three-year mortality was obtained using the spline method. When the aggravating factor was non-infection/non-ischemia, the appropriate NLR cut-off value of overall in-hospital mortality and post-discharge three-year mortality was 5; the adjusted ORs of overall in-hospital mortality and post-discharge three-year mortality were 2.12 (95% CI 1.33–3.37) and 1.61 (95% CI, 1.32–1.96), respectively (Table 6A). The in-hospital mortality and post-discharge three-year mortality curves were significantly different between NLR ≥ 5.0 and NLR < 5.0, as shown in Figure 3. However, when the aggravating factor was infection/ischemia, the appropriate NLR cut-off value of overall in-hospital mortality and post-discharge three-year mortality was 7; the adjusted ORs of in-hospital mortality and post-discharge three-year mortality were 1.91 (95% CI, 1.31–2.80) and 1.20 (95% CI, 1.03–1.47), respectively (Table 6B). The overall in-hospital mortality and post-discharge three-year mortality curves are shown in Figure 4.

4. Discussion

Our study shows important implication about the effect of NLR on in-hospital mortality and post-discharge mortality in patients with AHF. In AHF patients, higher NLR increases in-hospital mortality and mortality at one-month, six-month and three-year after discharge and NLR is an independent predictor for in-hospital and post-discharge three-year mortality.

In a previous study of approximately 1200 patients with acute decompensated heart failure followed up for 26 months, patients with higher NLR have significantly higher 30-day readmission and long-term mortality rate compared with those with lower NLR [10]. According to Benites-Zapata et al. [11], elevated NLR is related to increased mortality or heart transplantation risk in advanced HF. However, both studies are limited by small number of patients in single center and retrospective study.

Our study is a multi-center prospective study involving more than 5000 patients. In contrast to the two previous studies, we performed a subgroup analysis by the number of HF and the severity of LVEF according to the 2016 ESC guidelines. Regardless of the number of decompensated HF and the degree of LVEF, the higher the NLR, the worse the in-hospital mortality and the post-discharge three-year mortality. Particularly, as compared to the patients with HFrEF, the in-hospital and post-discharge three-year mortality were worse with increasing NLR in HFpEF patients. Considering the potential and emerging role of inflammation in HFpEF patients, NLR may be a good indicator for prognosis. In addition, a subgroup analysis was performed according to the aggravating factors of HF. In both infection/ischemia and non-infection/non-ischemia groups, in-hospital mortality and post-discharge three-year mortality were higher in the higher NLR group. As a result, NLR was independently associated with worse outcome.

No consensus has been reached on the cut-off values to define the levels of NLR as most studies classified into tertiles or quartiles. In our study, the cut-off value was 6, as calculated using the spline method. The cut-off value was different according to the aggravating factor of HF. When the aggravating factor was ischemia and/or infection, the cut-off value was 7 and the OR was 1.91 (95% CI, 1.31–2.80) in in-hospital mortality and 1.20 (95% CI, 1.03–1.47) in post-discharge three-year mortality. When the aggravating factor was not ischemia or infection, the cut-off value was 5 and the OR was 2.12 (95% CI, 1.33–3.37) in in-hospital mortality and 1.61 (95% CI, 1.32–1.96) in post-discharge three-year mortality.

As well known, BNP/NT_proBNP is an excellent marker for predicting prognosis in patients with heart failure [20,21]. However, there are a few problems for BNP, such as variability between kits and underestimation due to short-half life. NLR is inexpensive and has little variability during the test, compared to BNP. Furthermore, NLR can be usefully used in combination with BNP for various clinical settings.

We suggest two possible mechanisms why higher NLR increases all-cause mortality in patients with HF. First, NLR is an inflammatory marker. Second, NLR reflects sympathetic tone. NLR is a combination of two independent inflammatory markers involved in two different immune pathways: neutrophils as a marker of the ongoing nonspecific inflammation are involved with a much quicker response, and lymphocytes as a marker of the regulatory pathway are associated with more adaptive long-term response of the immune system, as called physiological stress [22,23,24]. When other different inflammatory stimulus occurs, Leukocytes in response release pro-inflammatory cytokines, such as acid phosphatase, elastase, and myeloperoxidase. The release of these cytokines has detrimental effects on the myocardium, which leads to decrease ventricular function [25,26,27]. By contrast, lymphocytes are related to the regulation of the immune system pathway [22]. Inflammation stimulate lymphocytopenia downregulation of the lymphocyte apoptosis, differentiation and lymphocyte proliferation, and neurohumoral activation [28,29]. Lymphopenia has been demonstrated to be an independent prognostic factor, being related to lower survival rates in patients with HF [6,30,31].

Another plausible mechanism is that NLR can be affected by autonomic nerve balance. In other words, a higher NLR could imply a higher ratio of sympathetic/parasympathetic tone. When sympathetic tone are stimulated, the number and function of granulocytes are increased. On the other hand, those of lymphocytes are increased by parasympathetic tone [32].

This study has several limitations. First, as the results were analyzed only with the NLR at the time of admission, evaluating the effect of changes in NLR values on clinical outcomes over time was not possible. Second, although multivariable adjustment was performed to clinical variable that are known to be significant, the possibility of potential confounders, such as nutritional status and concomitant inflammation caused by other comobidities, remains. Third, our study is a retrospective analysis of a prospective cohort, additional study might be needed. Fourth, adjustments to well-known factors of acute heart failure outcomes such as congestion may be lacking, and attention should be given to their interpretation.

5. Conclusions

NLR is a cost-effectiveness, easy to apply clinical applicable value that predicts short-term and three-year prognosis and stratifies the risk of patients with AHF. Elevated NLR in patients with AHF on admission is an independent predictor for in-hospital and post-discharge three-year mortality even if adjusted for well-known predictors and interactions. It is also independent predictor regardless of the severity of LVEF or aggravating factor of AHF. For practical and clinical applications, this study demonstrates the cut-off value of NLR to predict outcomes, instead of tertile or quartile values in the analyzed population. In general, the cut-off value of NLR is 6. When the exacerbation factor was infection or ischemia, the cut-off value of NLR is 7. However, when the exacerbation factor is not ischemia or infection, the cut-off value of NLR is 5. We suggest that our study results should be taken into consideration in treatment for patients with AHF in clinical settings.

Author Contributions

Conceptualization, J.H.C. and H.-J.C.; methodology, H.-Y.L.; resources and data curation, E.-S.J., K.-K.H., S.C.C., S.H.B., S.-M.K., D.-J.C., B.-S.Y., K.H.K., and J.-J.K.; statistical analysis, J.H.C. and Y.-J.K.; original draft preparation and writing, J.H.C. and H.-J.C.; funding acquisition, H.-Y.L. and B.-H.O. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants from the Research of Korea Centers for Disease Control and Prevention (2010-E63003-00, 2011-E63002-00, 2012-E63005-00, 2013-E63003-00, 2014-E63003-01, 2015-E63003-02, 2016-ER6303-00, and 2017-ER6303-01). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Conflicts of Interest

The authors declare no conflict of interest.

Figures, Scheme and Tables

Scheme 1. Study population.

Figure 1. Overall in-hospital mortality and 3-year survival after discharge. Quartile 1 (0.2–2.0); Quartile 2 (2.1–3.2), Quartile 3 (3.3–5.8), Quartile 4 (5.9–192,4).

Figure 2. Overall in-hosptial mortality and 3-year survival after discharge of HF patients subgroup analysis by aggravating factor. (A) Quartile 1 (0.2–1.9), Quartile 2 (2.0–2.9), Quartile 3 (3.0–4.9), Quartile 4 (5.0–95.0); (B) Quartile 1 (0.2–2.3), Quartile 2 (2.4–3.8), Quartile 3 (3.9–7.0), Quartile 4 (7.1–192.4).

Figure 3. Overall in-hosptial mortality and 3-year survival after discharge of HF patients whose aggravating factor were not-infection or non-ischemia divided by NLR 5.0.

Figure 4. Overall in-hosptial mortality and 3-year survival after discharge of HF patients whose aggravating factor were infection or ischemia divided by NLR 5.0.

Table 1

Baseline clinical characteristics of heart failure (HF) patients stratified by quartiles of neutrophil to lymphocyte ratio at admission.

Clinical Characteristic	Neutrophil to Lymphocyte Ratio				p Value
	Quartile 1(0.2–2.0)(n = 1395)	Quartile 2(2.1–3.2)(n = 1395)	Quartile 3(3.3–5.8)(n = 1395)	Quartile 4(5.9–192.4)(n = 1395)
Age (years)	64.9 ± 14.8	67.6 ± 14.5	70.2 ± 13.6	71.2 ± 14.2	<0.001
Male	739 (53.0%)	732 (52.5%)	750 (53.8%)	743 (53.3%)	0.921
de novo HF	755 (54.1%)	725 (52.0%)	671 (48.1%)	760 (54.5%)	0.002
BMI	23.9 ± 3.8	23.6 ± 3.8	23.2 ± 4.0	22.6 ± 3.8	<0.001
Current smoker	312 (22.4%)	230 (16.5%)	213 (15.3%)	228 (16.3%)	<0.001
Clinical Presentation
Systolic BP (mmHg)	130.3 ± 31.4	131.7 ± 29.0	131.3 ± 30.6	131.2 ± 30.1	0.676
Diastolic BP (mmHg)	79.6 ± 19.0	79.2 ± 18.6	78.5 ± 18.6	77.0 ± 18.8	0.002
Heart rate (beats/min)	91.2 ± 27.5	90.7 ± 25.4	91.9 ± 25.5	97.0 ± 24.8	<0.001
NYHA III/IV	1100 (78.9%)	1153 (82.7%)	1219 (87.4%)	1265 (90.7%)	<0.001
LVEF (%)	37.4 ± 15.9	36.6 ± 15.4	38.2 ± 15.5	38.2 ± 15.2	0.018
Past Medical History
Hypertension	761 (54.6%)	873 (62.6%)	902 (64.7%)	928 (66.5%)	<0.001
Diabetes mellitus	431 (30.9%)	545 (39.1%)	591 (42.4%)	663 (47.5%)	<0.001
Ischemic Heart Disease.	513 (36.8%)	571 (40.9%)	636 (45.6%)	670 (48.0%)	<0.001
Prior admission due to HF	396 (28.4%)	432 (31.0%)	506 (36.3%)	467 (33.5%)	<0.001
Arrhythmia	433 (31.1%)	492 (35.3%)	509 (36.5%)	425 (30.5%)	0.001
Cerebrovascular Disease	166 (11.9%)	204 (14.6%)	232 (16.6%)	243 (17.4%)	<0.001
Etiology of HF
Ischemic	439 (31.5%)	508 (36.4%)	556 (39.9%)	594 (42.6%)	<0.001
Valvular	189 (13.5%)	199 (14.3%)	237 (17.0%)	178 (12.8%)	0.009
Dilated cardiomyopathy	367 (26.3%)	308 (22.1%)	227 (16.3%)	248 (17.8%)	<0.001
Hypertensive	49 (3.5%)	54 (3.9%)	60 (4.3%)	54 (3.9%)	0.761
Tachycardia (AF) related	165 (11.8%)	150 (10.8%)	160 (11.5%)	117 (8.4%)	0.014
Others	186 (13.3%)	176 (12.6%)	155 (11.1%)	204 (14.6%)	0.046
Blood chemistry
Hemoglobin (g/dL)	13.1 ± 2.2	12.6 ± 2.3	12.1 ± 2.3	11.8 ± 2.3	<0.001
WBC count (× 1000/uL)	7.5 ± 3.2	7.5 ± 3.0	8.5 ± 3.2	11.3 ± 5.2	<0.001
Platelet count (× 103/uL)	207.4 ± 75.7	208.8 ± 79.6	207.3 ± 78.6	218.6 ± 115.6	0.001
Albumin (g/dL)	3.8 ± 0.5	3.7 ± 0.5	3.6 ± 0.5	3.5 ± 0.5	<0.001
Na (mEq/L)	139.0 ± 3.8	138.1 ± 4.2	137.0 ± 4.9	135.9 ± 5.7	<0.001
BUN (mg/dL)	21.0 ± 11.8	24.1 ± 13.9	27.9 ± 17.4	31.8 ± 19.5	<0.001
Cr (mg/dL)	1.2 ± 1.1	1.4 ± 1.3	1.5 ± 1.5	1.8 ± 1.9	<0.001
eGFR (mL/min/1.73 m2)	73.3 ± 30.8	68.1 ± 37.1	63.4 ± 34.5	58.0 ± 35.4	<0.001
BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL	857 (61.4%)	981 (70.3%)	1027 (73.6%)	1117 (80.1%)	<0.001
Medication at admission
ACEi/ARB	533 (38.2%)	551 (39.5%)	568 (40.7%)	484 (34.7%)	0.007
Beta blocker	415 (29.7%)	402 (29.8%)	427 (30.6%)	340 (24.4%)	0.001
Aldosterone antagonist	249 (17.8%)	263 (18.9%)	279 (20.0%)	256 (18.4%)	0.507
Mechanical ventilation	214 (15.3%)	161 (11.5%)	196 (14.1%)	288 (20.6%)	<0.001
Renal replacement Tx.	63 (4.5%)	68 (4.9%)	109 (7.8%)	183 (13.1%)	<0.001
Mechanical circulatory support	80 (5.7%)	64 (4.6%)	78 (5.6%)	110 (7.9%)	0.002
In-hospital mortality, n (%)(including urgent heart TPL)	58 (4.2%)	52 (3.7%)	83 (5.9%)	138 (9.9%)	<0.001

BMI, body mass index; BP, blood pressure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; HF, heart failure; AF, atrial fibrillation; WBC, white blood cells; BUN; blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; NT-proBNP, n-terminal brain natriuretic peptide; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; Tx., therapy; TPL, transplantation.

Table 2

Univariate and multivariate logistic regression analyses for all-cause in-hospital and Cox regression analysis for post discharge three-years mortality in HF patients stratified by quartiles of neutrophil to lymphocyte ratio at admission. HF, heart failure; NT-proBNP, n-terminal brain natriuretic peptide; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; BNP, brain natriuretic peptide; AA, aldosterone antagonist; BB, beta blocker; RASi, renin-angiotensin system inhibitor.

	In-Hospital Mortality (n = 5580)		Post Discharge 3 Year Mortality (n = 5312)
	Adjusted OR a	p Value	Adjusted OR b	p Value
Quartile 1 (0.2–2.0)	1.0 (Ref.)		1.0 (Ref.)
Quartile 2 (2.1–3.2)	0.86 (0.52–1.42)	0.549	1.11(0.96–1.29)	0.172
Quartile 3 (3.3–5.8)	1.17 (0.73–1.87)	0.514	1.35 (1.16–1.55)	<0.001
Quartile 4 (5.9–192.4)	2.23 (1.44–3.44)	<0.001	1.44 (1.24–1.67)	<0.001

Data are expressed as odds ratio (OR) and 95% confidence intervals (CI). Ref. = reference category.^a adjusted for age category (70> vs. 70≤), sex (male vs. female), body mass index category (25> vs. 23≤), etiology of heart failure (ischemic vs. non-ischemic), systolic blood pressure (100> vs. 100≤), history of hypertension, history of diabetes mellitus, history of cerebrovascular disease, history of chronic obstructive disease, prior admission history due to HF, presented tachyarrhythmia on admission, sodium level (135> vs. 135≤), creatinine level (2.0> vs. 2.0≤), left ventricular ejection fraction (HFrEF vs HFmrEF vs HFpEF), BNP ≥ 500 pg/mL or NT-proBNP ≥1 500 pg/mL. ^b adjusted for age category (70> vs. 70≤), sex (male vs. female), body mass index category (23> vs. 23≤), etiology of heart failure (ischemic vs. non-ischemic), systolic blood pressure (100> vs. 100≤), history of hypertension, history of diabetes mellitus, history of cerebrovascular disease, history of chronic obstructive disease, prior admission history due to HF, presented tachyarrhythmia on admission, sodium level (135> vs. 135≤), creatinine level (2.0> vs. 2.0≤), left ventricular ejection fraction (HFrEF vs. HFmrEF vs. HFpEF), BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL, AA, BB, RASi.

Table 3

Baseline clinical characteristics of HF patients whose aggravating factor were not infection or ischemia stratified by quartiles of neutrophil to lymphocyte ratio at admission. HF, heart failure; BMI, body mass index; BP, blood pressure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; HF, heart failure; AF, atrial fibrillation; WBC, white blood cells; BUN; blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; NT-proBNP, n-terminal brain natriuretic peptide; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; Tx., therapy; TPL, transplantation.

Clinical Characteristic	Neutrophil to Lymphocyte Ratio				p Value
	Quartile 1(0.2–1.9)(n = 782)	Quartile 2(2.0–2.9)(n = 783)	Quartile 3(3.0–4.9)(n = 781)	Quartile 4(5.0–95.0)(n = 781)
Age (years)	63.2 ± 15.6	66.3 ± 15.2	69.0 ± 14.5	69.1 ± 15.6	<0.001
Male	391 (50.0%)	393 (50.2%)	387 (49.6%)	397 (50.8%)	0.967
de novo HF	405 (51.8%)	384 (49.0%)	330 (42.3%)	355 (45.5%)	0.001
BMI	24.1 ± 4.0	23.7 ± 3.9	23.4 ± 4.1	22.9 ± 4.2	<0.001
Current smoker	166 (21.2%)	128 (16.3%)	102 (13.1%)	116 (14.9%)	<0.001
Clinical Presentation
Systolic BP (mmHg)	128.0 ± 29.4	130.4 ± 28.5	130.3 ±30.3	130.8 ± 31.3	0.226
Diastolic BP (mmHg)	79.0 ± 18.6	19.6 ± 19.1	78.6 ± 18.9	77.2 ± 19.7	0.083
Heart rate (beats/min)	91.0 ± 27.9	90.6 ± 27.4	91.7 ± 27.4	94.9 ± 27.6	0.009
NYHA III/IV	607 (77.6%)	632 (80.7%)	678 (86.8%)	678 (86.8%)	<0.001
LVEF (%)	37.5 ± 16.7	37.2 ± 16.4	39.4 ± 16.7	39.2 ± 16.6	0.015
Past Medical History
Hypertension	412 (52.7%)	453 (57.9%)	477 (61.1%)	477 (61.1%)	0.002
Diabetes mellitus	209 (26.7%)	247 (31.5%)	281 (36.0%)	308 (39.4%)	<0.001
Ischemic Heart Disease.	147 (18.8%)	177 (22.6%)	183 (23.4%)	196 (25.1%)	0.023
Prior admission due to HF	230 (29.4%)	256 (32.7%)	320 (41.0%)	316 (40.5%)	<0.001
Arrhythmia	281 (36.0%)	329 (42.1%)	357 (45.7%)	315 (40.3%)	0.001
Cerebrovascular Disease	86 (11.0%)	115 (14.7%)	108 (13.8%)	136 (17.4%)	0.004
Etiology of HF
Ischemic	93 (11.9%)	131 (16.7%)	128 (16.4%)	134 (17.2%)	0.013
Valvular	134 (17.1%)	138 (17.6%)	185 (23.7%)	152 (19.5%)	0.004
Dilated cardiomyopathy	255 (32.6%)	218 (27.8%)	180 (23.0%)	196 (25.1%)	<0.001
Hypertensive	37 (4.7%)	40 (5.1%)	43 (5.5%)	42 (5.4%)	0.906
Tachycardia (AF) related	119 (15.2%)	134 (17.1%)	124 (15.9%)	105 (13.4%)	0.240
Others	144 (18.4%)	122 (15.6)%	121 (15.5%)	152 (19.5%)	0.084
Blood chemistry
Hemoglobin (g/dL)	13.2 ± 2.3	12.8 ± 2.2	12.3 ± 2.3	12.0 ± 2.4	<0.001
WBC count (× 1000/uL)	7.0 ± 2.8	7.0 ± 24	7.6 ± 2.7	101.9 ± 5.2	<0.001
Platelet count (× 103/uL)	201.5 ± 75.0	197.1 ± 69.0	201.0 ± 77.1	207.9 ± 110.8	0.092
Albumin (g/dL)	3.8 ± 0.4	3.8 ± 0.4	3.7 ± 0.5	3.6 ± 0.5	<0.001
Na (mEq/L)	139.0 ± 3.6	138.4 ± 4.2	137.1 ± 5.0	136.1 ± 5.8	<0.001
BUN (mg/dL)	21.0 ± 11.7	23.3 ± 13.1	27.5 ± 16.5	32.9 ± 22.0	<0.001
Cr (mg/dL)	1.1 ± 1.0	1.3 ± 1.2	1.5 ± 1.5	1.7 ± 1.9	<0.001
eGFR (mL/min/1.73 m2)	76.1 ± 32.1	68.5 ± 34.2	63.1 ± 33.8	59.7 ± 35.0	<0.001
BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL	474 (60.6%)	552 (70.5%)	557 (71.3%)	612 (78.4%)	<0..001
Medication at admission
ACEi/ARB	310 (39.6%)	309 (39.5%)	330 (42.3%)	288 (36.9%)	0.193
Beta blocker	241 (30.8%)	224 (28.6%)	229 (29.3%)	211 (27.0%)	0.416
Aldosterone antagonist	165 (21.1%)	172 (22.0%)	197 (5.2%)	163 (16.9%)	0.140
Mechanical ventilation	83 (10.6%)	68 (8.7%)	82 (10.5%)	106 (13.6%)	0.019
Renal replacement Tx.	19 (2.4%)	26 (3.3%)	56 (7.2%)	86 (11.0%)	<0.001
Mechanical circulatory support	25 (3.2%)	21 (2.7%)	27 (3.5%)	36 (4.6%)	0.201
Total mortality, N (%)(including urgent heart TPL)	21 (2.7%)	23 (2.9%)	40 (5.1%)	65 (8.3%)	<0.001

Table 4

Univariate and multivariate logistic regression analyses for all-cause in-hospital and post discharge 3-year mortality in HF patients subgroup analysis by aggravating factor. HF, heart failure; NT-proBNP, n-terminal brain natriuretic peptide; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; BNP, brain natriuretic peptide; AA, aldosterone antagonist; BB, beta blocker; RASi, renin-angiotensin system inhibitor.

(A) Patients Whose Aggravating Factor Were not Infection or Ischemia.
	In-Hospital Mortality (n = 3127)		Post Discharge 3 Year Mortality (n = 3026)
	Adjusted OR a	p Value	Adjusted OR b	p Value
Quartile 1 (0.2–1.9)	1.0 (Ref.)		1.0 (Ref.)
Quartile 2 (2.0–2.9)	0.85 (0.37–1.96)	0.702	0.98 (0.76–1.27)	0.868
Quartile 3 (3.0–4.9)	1.41 (0.67–2.96)	0.365	1.38 (1.07–1.77)	0.014
Quartile 4 (5.0–95.0)	2.39 (1.19–4.81)	0.015	1.81 (1.40–2.35)	<0.001
(B) Patients Whose Aggravating Factor Were Infection or Ischemia
	In-Hospital Mortality (n = 2453)		Post Discharge 3 Year Mortality (n = 2286)
	Adjusted OR a	p Value	Adjusted OR b	p Value
Quartile 1 (0.2–2.3)	1.0 (Ref.)		1.0 (Ref.)
Quartile 2 (2.4–3.8)	0.83 (0.43–1.62)	0.590	1.01 (0.77–1.34)	0.971
Quartile 3 (3.9–7.0)	1.65 (0.91–2.93)	0.099	1.18 (0.89–1.55)	0.288
Quartile 4 (7.1–192.4)	2.24 (1.26–4.00)	0.006	1.30 (1.05–1.73)	0.027

Data are expressed as odds ratio (OR) and 95% confidence intervals (CI). Ref. = reference category. ^a adjusted for age category (70> vs. 70≤), sex (male vs. female), body mass index category (25> vs. 23≤), etiology of heart failure (ischemic vs. non-ischemic), systolic blood pressure (100> vs. 100≤), history of hypertension, history of diabetes mellitus, history of cerebrovascular disease, history of chronic obstructive disease, prior admission history due to HF, presented tachyarrhythmia on admission, sodium level (135> vs. 135≤), creatinine level (2.0> vs. 2.0≤), left ventricular ejection fraction (HFrEF vs. HFmrEF vs. HFpEF), BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL. ^b adjusted for age category (70> vs. 70≤), sex (male vs. female), body mass index category (23> vs. 23≤), etiology of heart failure (ischemic vs. non-ischemic), systolic blood pressure (100> vs. 100≤), history of hypertension, history of diabetes mellitus, history of cerebrovascular disease, history of chronic obstructive disease, prior admission history due to HF, presented tachyarrhythmia on admission, sodium level (135> vs. 135≤), creatinine level (2.0> vs. 2.0≤), left ventricular ejection fraction (HFrEF vs. HFmrEF vs. HFpEF), BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL, AA, BB, RASi.

Table 5

Baseline clinical characteristics of HF patients whose aggravating factor were infection or ischemia stratified by quartiles of neutrophil to lymphocyte ratio at admission. HF, heart failure; BMI, body mass index; BP, blood pressure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; HF, heart failure; AF, atrial fibrillation; WBC, white blood cells; BUN; blood urea nitrogen; Cr, creatinine; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; NT-proBNP, n-terminal brain natriuretic peptide; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; Tx., therapy; TPL, transplantation.

Clinical Characteristic	Neutrophil to Lymphocyte Ratio				p Value
	Quartile 1(0.2–2.3)(n = 613)	Quartile 2(2.4–3.8)(n = 614)	Quartile 3(3.9–7.0)(n = 613)	Quartile 4(7.1–192.4)(n = 613)
Age (years)	67.8 ± 12.9	69.9 ± 13.1	71.2 ± 12.9	73.0 ± 12.3	<0.001
Male (%)	356 (58.1%)	363 (59.1%)	348 (56.8%)	329 (53.7%)	0.242
De novo HF	381 (62.2%)	339 (55.2%)	350 (57.1%)	367 (59.9%)	0.070
BMI	23.6 ± 3.6	23.2 ± 3.4	23.1 ± 4.0	22.3 ± 3.3	<0.001
Current smoker	151 (24.6%)	104 (16.9%)	116 (18.9%)	100 (16.3%)	0.001
Clinical Presentation
Systolic BP (mmHg)	134.8 ± 34.2	132.9 ± 29.0	133.3 ± 29.6	129.9 ± 29.7	0.046
Diastolic BP (mmHg)	80.3 ± 19.3	79.1 ± 17.9	79.1 ± 17.6	75.8 ± 18.0	<0.001
Heart rate (beats/min)	91.6 ± 25.5	91.1 ± 22.1	92.9 ± 21.9	98.7 ± 24.0	<0.001
NYHA III/IV	489 (79.8%)	534 (87.0%)	544 (88.7%)	575 (93.8%)	<0.001
LVEF (%)	36.7 ± 14.4	35.5 ± 13.4	37.0 ± 14.1	37.6 ± 13.7	0.063
Past Medical History
Hypertension	365 (59.5%)	423 (68.9%)	429 (70.0%)	428 (69.8%)	<0.001
Diabetes mellitus	257 (41.9%)	300 (48.9%)	309 (50.4%)	319 (52.0%)	0.002
Ischemic Heart Dz.	429 (70.0%)	431 (70.2%)	432 (70.5%)	395 (64.4%)	0.066
Prior adm. Hx. d/t HF	140 (22.8%)	177 (28.8%)	183 (29.9%)	179 (29.2%)	0.021
Arrhythmia	121 (19.7%)	144 (23.5%)	164 (26.8%)	148 (24.1%)	0.036
Cerebrovascular Dz.	76 (12.4%)	95 (15.5%)	110 (17.9%)	119 (19.4%)	0.005
Etiology of HF
Ischemic	414 (67.5%)	416 (67.8%)	409 (66.7%)	372 (60.7%)	0.027
Valvular	40 (6.5%)	46 (7.5%)	50 (8.2%)	58 (9.5%)	0.279
Dilated cardiomyopathy	101 (16.5%)	64 (10.4%)	60 (9.8%)	76 (12.4%)	0.001
Hypertensive	9 (1.5%)	12 (2.0%)	17 (2.8%)	17 (2.8%)	0.323
Tachycardia (AF) related	21 (3.4%)	29 (4.7%)	33 (5.4%)	27 (4.4%)	0.415
Others	28 (4.6%)	47 (7.7%)	44 (7.2%)	63 (10.3%)	0.002
Blood chemistry
Hemoglobin (g/dL)	13.0 ± 2.2	12.2 ± 2.2	12.0 ± 2.2	11.7 ± 2.2	<0.001
WBC count (× 1000/uL)	8.3 ± 3.5	8.3 ± 3.7	9.6 ± 3.7	12.3 ± 5.0	<0.001
Platelet count (× 103/uL)	221.6 ± 80.5	222.9 ± 81.8	216.9 ± 87.8	225.0 ± 117.7	0.476
Albumin (g/dL)	3.8 ± 0.5	3.7 ± 0.5	3.6 ± 0.5	3.5 ± 0.5	<0.001
Na (mEq/L)	138.8 ± 4.0	137.8 ± 4.0	136.9 ± 4.7	135.7 ± 5.7	<0.001
BUN (mg/dL)	21.0 ± 11.5	24.8 ± 13.3	27.6 ± 17.0	32.0 ± 18.4	<0.001
Cr (mg/dL)	1.3 ± 1.2	1.5 ± 1.3	1.6 ± 1.6	1.8 ± 1.7	<0.001
eGFR (mL/min/1.73 m2)	71.0 ± 29.6	66.5 ± 39.1	63.4 ± 36.0	56.1 ± 35.8	<0.001
BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL	377 (61.5%)	445 (72.5%)	470 (76.7%)	495 (80.8%)	<0.001
Medication at admission
ACEi/ARB	219 (35.7%)	250 (40.7%)	228 (37.2%)	202 (33.0%)	0.040
Beta blocker	167 (27.2%)	189 (30.8%)	187 (30.5%)	136 (22.2%)	0.002
Aldosterone antagonist	69 (11.3%)	76 (12.4%)	97 (15.8%)	108 (17.6%)	0.004
Mechanical ventilation	148 (24.1%)	88 (14.3%)	116 (18.9%)	168 (27.4%)	<0.001
Renal replacement Tx.	44 (7.2%)	40 (6.5%)	68 (11.1%)	84 (13.7%)	<0.001
Mechanical circulatory support	62 (10.1%)	43 (7.0%)	56 (9.1%)	62 (10.1%)	0.188
Total mortality, N (%)(including urgent heart TPL)	38 (6.2%)	24 (3.9%)	51 (8.3%)	69 (11.3%)	<0.001

Table 6

Univariate and multivariate logistic regression analyses for all-cause in-hospital and post discharge 3-year mortality in HF patients subgroup analysis by aggravating factor stratified by neutrophil-lymphocyte ratio (NLR) cutoff value.

(A) Patients Whose Aggravating Factor Were not Infection or Ischemia
	In-Hospital Mortality (n = 3127)		Post Discharge 3 Year Mortality (n = 3026)
	Unadjusted OR	Adjusted OR a	Unadjusted OR	Adjusted OR b
NLR < 5.0	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
NLR ≥ 5.0	3.35 (2.25–4.99)	2.12 (1.33–3.37)	1.90 (1.67–2.17)	1.61 (1.32–1.96)
(B) Patients Whose Aggravating Factor Were Infection or Ischemia
	In-Hospital Mortality (n = 2453)		Post Discharge 3 Year Mortality (n = 2286)
	Unadjusted OR	Adjusted OR a	Unadjusted OR	Adjusted OR b
NLR < 7.0	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)	1.0 (Ref.)
NLR ≥ 7.0	2.11 (1.52–2.91)	1.91 (1.31–2.80)	1.56 (1.35–1.80)	1.20 (1.03–1.47)

Data are expressed as odds ratio (OR) and 95% confidence intervals (CI). Ref. = reference category.^a adjusted for age category (70> vs. 70≤), sex (male vs. female), body mass index category (25> vs. 23≤), etiology of heart failure (ischemic vs. non-ischemic), systolic blood pressure (100> vs. 100≤), history of hypertension, history of diabetes mellitus, history of cerebrovascular disease, history of chronic obstructive disease, prior admission history due to HF, presented tachyarrhythmia on admission, sodium level (135> vs. 135≤), creatinine level (2.0> vs. 2.0≤), left ventricular ejection fraction (40%> vs. 40%≤), BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL.^b adjusted for age category (70> vs. 70≤), sex (male vs. female), body mass index category (25> vs. 23≤), etiology of heart failure (ischemic vs. non-ischemic), systolic blood pressure (100> vs. 100≤), history of hypertension, history of diabetes mellitus, history of cerebrovascular disease, history of chronic obstructive disease, prior admission history due to HF, presented tachyarrhythmia on admission, sodium level (135> vs. 135≤), creatinine level (2.0> vs. 2.0≤), left ventricular ejection fraction (40%> vs. 40%≤), BNP ≥ 500 pg/mL or NT-proBNP ≥ 1500 pg/mL, AA, BB, RASi. HF, heart failure; NT-proBNP, n-terminal brain natriuretic peptide; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; BNP, brain natriuretic peptide; AA, aldosterone antagonist; BB, beta blocker; RASi, renin-angiotensin system inhibitor.

Supplementary Materials

The following are available online at https://www.mdpi.com/2077-0383/9/2/557/s1. Figure S1: Overall in-hospital mortality and post discharge 3-year mortality in HF patients subgroup analysis by de novo HF versus worsening of pre-existing HF, Figure S2: Overall in-hospital mortality and post discharge 3-year mortality in HF patients subgroup analysis by LVEF categories, Table S1: In-hospital clinical outcomes stratified by quartiles of neutrophil to lymphocyte ratio at admission, Table S2: Univariate and multivariate logistic regression analyses for all-cause in-hospital and post discharge 3-years mortality in HF Patients subgroup analysis by de novo HF versus worsening of pre-existing HF., Table S3: Univariate and multivariate logistic regression analyses for all-cause in-hospital and post discharge 3-years mortality in HF Patients subgroup analysis by LVEF categories., Table S4: In-hospital clinical outcomes of HF patients whose aggravating factor were not infection or ischemia stratified by quartiles of neutrophil to lymphocyte ratio at admission, Table S5: In-hospital clinical outcomes of HF patients whose aggravating factor were infection or ischemia stratified by quartiles of neutrophil to lymphocyte ratio at admission. Table S6: Univariate and multivariate logistic regression analyses for all-cause in-hospital and Cox regression analysis for post discharge 3-years mortality in HF Patients stratified by quartiles of neutrophil to lymphocyte ratio at admission. Table S7: Univariate and multivariate logistic regression analyses for all-cause in-hospital and post discharge 3-year mortality in HF Patients subgroup analysis by aggravating factor.

References

1. Braunwald, E. Biomarkers in heart failure. N. Engl. J. Med.; 2008; 358, pp. 2148-2159. [DOI: https://dx.doi.org/10.1056/NEJMra0800239]

2. Horne, B.D.; Anderson, J.L.; John, J.M.; Weaver, A.; Bair, T.L.; Jensen, K.R.; Renlund, D.G.; Muhlestein, J.B. Intermountain Heart Collaborative Study Group. Which white blood cell subtypes predict increased cardiovascular risk?. J. Am. Coll. Cardiol.; 2005; 45, pp. 1638-1643. [DOI: https://dx.doi.org/10.1016/j.jacc.2005.02.054]

3. Engstrom, G.; Melander, O.; Hedblad, B. Leukocyte count and incidence of hospitalizations due to heart failure. Circ. Heart Fail.; 2009; 2, pp. 217-222. [DOI: https://dx.doi.org/10.1161/CIRCHEARTFAILURE.108.827071]

4. Arruda-Olson, A.M.; Reeder, G.S.; Bell, M.R.; Weston, S.A.; Roger, V.L. Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study. Circ. Cardiovasc. Qual. Outcomes; 2009; 2, pp. 656-662. [DOI: https://dx.doi.org/10.1161/CIRCOUTCOMES.108.831024]

5. Ommen, S.R.; Hammill, S.C.; Gibbons, R.J. The relative lymphocyte count predicts death in patients receiving implantable cardioverter defibrillators. Pacing Clin. Electrophysiol.; 2002; 25, pp. 1424-1428. [DOI: https://dx.doi.org/10.1046/j.1460-9592.2002.01424.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12418738]

6. Ommen, S.R.; Hodge, D.O.; Rodeheffer, R.J.; McGregor, C.G.; Thomson, S.P.; Gibbons, R.J. Predictive power of the relative lymphocyte concentration in patients with advanced heart failure. Circulation; 1998; 97, pp. 19-22. [DOI: https://dx.doi.org/10.1161/01.CIR.97.1.19] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9443426]

7. Afari, M.E.; Bhat, T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev. Cardiovasc. Ther.; 2016; 14, pp. 573-577. [DOI: https://dx.doi.org/10.1586/14779072.2016.1154788] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26878164]

8. Kim, S.; Eliot, M.; Koestler, D.C.; Wu, W.C.; Kelsey, K.T. Association of neutrophil-to-lymphocyte ratio with mortality and cardiovascular disease in the Jackson Heart Study and modification by the Duffy antigen variant. JAMA Cardiol.; 2018; 3, pp. 455-462. [DOI: https://dx.doi.org/10.1001/jamacardio.2018.1042]

9. Park, J.J.; Jang, H.J.; Oh, I.Y.; Yoon, C.H.; Suh, J.W.; Cho, Y.S.; Youn, T.J.; Cho, G.Y.; Chae, I.H.; Choi, D.J. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am. J. Cardiol.; 2013; 111, pp. 636-642. [DOI: https://dx.doi.org/10.1016/j.amjcard.2012.11.012]

10. Uthamalingam, S.; Patvardhan, E.A.; Subramanian, S.; Ahmed, W.; Martin, W.; Daley, M.; Capodilupo, R. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am. J. Cardiol.; 2011; 107, pp. 433-438. [DOI: https://dx.doi.org/10.1016/j.amjcard.2010.09.039]

11. Benites-Zapata, V.A.; Hernandez, A.V.; Nagarajan, V.; Cauthen, C.A.; Starling, R.C.; Tang, W.H. Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure. Am. J. Cardiol.; 2015; 115, pp. 57-61. [DOI: https://dx.doi.org/10.1016/j.amjcard.2014.10.008] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25456873]

12. Lee, S.E.; Cho, H.J.; Lee, H.Y.; Yang, H.M.; Choi, J.O.; Jeosn, E.S.; Kim, M.S.; Kim, J.J.; Hwang, K.K.; Chae, S.C. et al. A multicentre cohort study of acute heart failure syndromes in Korea: rationale, design, and interim observations of the Korean Acute Heart Failure (KorAHF) registry. Eur. J. Heart Fail.; 2014; 16, pp. 700-708. [DOI: https://dx.doi.org/10.1002/ejhf.91] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24797348]

13. Lee, S.E.; Lee, H.Y.; Cho, H.J.; Choe, W.S.; Kim, H.; Choi, J.O.; Jeon, E.S.; Kim, M.S.; Kim, J.J.; Hwang, K.K. et al. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure Registry (KorAHF). Korean Circ. J.; 2017; 47, pp. 341-353. [DOI: https://dx.doi.org/10.4070/kcj.2016.0419] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28567084]

14. Cho, J.H.; Choe, W.S.; Cho, H.J.; Lee, H.Y.; Jang, J.; Lee, S.E.; Choi, J.O.; Jeon, E.S.; Kim, M.S.; Hwang, K.K. et al. Comparison of Characteristics and 3-Year Outcomes in Patients With Acute Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. Circ. J.; 2019; 83, pp. 347-356. [DOI: https://dx.doi.org/10.1253/circj.CJ-18-0543]

15. Teerlink, J.R.; Voors, A.A.; Ponikowski, P.; Pang, P.S.; Greenberg, B.H.; Filippatos, G.; Felker, G.M.; Davison, B.A.; Cotter, G.; Gimpelewicz, C. et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur. J. Heart Fail.; 2017; 19, pp. 800-809. [DOI: https://dx.doi.org/10.1002/ejhf.830]

16. Henry, B.L.; Schwartzman, D.S.; Salama, G. Mode of death prevention by serelaxin. J. Am. Coll. Cardiol.; 2015; 66, pp. 98-99. [DOI: https://dx.doi.org/10.1016/j.jacc.2014.12.079]

17. Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; Gonzalez-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev. Esp. Cardiol. (Engl. Ed.); 2016; 69, 1167.

18. Cardinal, T.R.; Vigo, A.; Duncan, B.B.; Matos, S.M.A.; da Fonseca, M.J.M.; Barreto, S.M.; Schmidt, M.I. Optimal cut-off points for waist circumference in the definition of metabolic syndrome in Brazilian adults: baseline analyses of the Longitudinal Study of Adult Health (ELSA-Brasil). Diabetol. Metab. Syndr.; 2018; 10, 49. [DOI: https://dx.doi.org/10.1186/s13098-018-0347-0]

19. Ravi, B.; Jenkinson, R.; Austin, P.C.; Croxford, R.; Wasserstein, D.; Escott, B.; Paterson, J.M.; Kreder, H.; Hawker, G.A. Relation between surgeon volume and risk of complications after total hip arthroplasty: propensity score matched cohort study. BMJ; 2014; 348, g3284. [DOI: https://dx.doi.org/10.1136/bmj.g3284]

20. van Veldhuisen, D.J.; Linssen, G.C.; Jaarsma, T.; van Gilst, W.H.; Hoes, A.W.; Tijssen, J.G.; Paulus, W.J.; Voors, A.A.; Hillege, H.L. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J. Am. Coll. Cardiol.; 2013; 61, pp. 1498-1506. [DOI: https://dx.doi.org/10.1016/j.jacc.2012.12.044]

21. Daniels, L.B.; Maisel, A.S. Natriuretic peptides. J. Am. Coll. Cardiol.; 2007; 50, pp. 2357-2368. [DOI: https://dx.doi.org/10.1016/j.jacc.2007.09.021] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18154959]

22. Azab, B.; Zaher, M.; Weiserbs, K.F.; Torbey, E.; Lacossiere, K.; Gaddam, S.; Gobunsuy, R.; Jadonath, S.; Baldari, D.; McCord, D. et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am. J. Cardiol.; 2010; 106, pp. 470-476. [DOI: https://dx.doi.org/10.1016/j.amjcard.2010.03.062] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20691303]

23. Nunez, J.; Nunez, E.; Bodi, V.; Sanchis, J.; Minana, G.; Mainar, L.; Santas, E.; Merlos, P.; Rumiz, E.; Darmofal, H. et al. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am. J. Cardiol.; 2008; 101, pp. 747-752. [DOI: https://dx.doi.org/10.1016/j.amjcard.2007.11.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18328833]

24. Angkananard, T.; Anothaisintawee, T.; McEvoy, M.; Attia, J.; Thakkinstian, A. Neutrophil lymphocyte ratio and cardiovascular disease risk: a systematic review and meta-analysis. Biomed. Res. Int.; 2018; 2018, 2703518. [DOI: https://dx.doi.org/10.1155/2018/2703518]

25. Tang, W.H.; Tong, W.; Troughton, R.W.; Martin, M.G.; Shrestha, K.; Borowski, A.; Jasper, S.; Hazen, S.L.; Klein, A.L. Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J. Am. Coll. Cardiol.; 2007; 49, pp. 2364-2370. [DOI: https://dx.doi.org/10.1016/j.jacc.2007.02.053]

26. Chen, W.; Frangogiannis, N.G. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail. Rev.; 2010; 15, pp. 415-422. [DOI: https://dx.doi.org/10.1007/s10741-010-9161-y]

27. Briasoulis, A.; Androulakis, E.; Christophides, T.; Tousoulis, D. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail. Rev.; 2016; 21, pp. 169-176. [DOI: https://dx.doi.org/10.1007/s10741-016-9533-z]

28. Nunez, J.; Minana, G.; Bodi, V.; Nunez, E.; Sanchis, J.; Husser, O.; Llacer, A. Low lymphocyte count and cardiovascular diseases. Curr. Med. Chem.; 2011; 18, pp. 3226-3233. [DOI: https://dx.doi.org/10.2174/092986711796391633]

29. Mooren, F.C.; Bloming, D.; Lechtermann, A.; Lerch, M.M.; Volker, K. Lymphocyte apoptosis after exhaustive and moderate exercise. J. Appl. Physiol. (1985); 2002; 93, pp. 147-153. [DOI: https://dx.doi.org/10.1152/japplphysiol.01262.2001]

30. Ommen, S.R.; Gibbons, R.J.; Hodge, D.O.; Thomson, S.P. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. Am. J. Cardiol.; 1997; 79, pp. 812-814. [DOI: https://dx.doi.org/10.1016/S0002-9149(96)00878-8]

31. Durmus, E.; Kivrak, T.; Gerin, F.; Sunbul, M.; Sari, I.; Erdogan, O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. Arq. Bras. Cardiol.; 2015; 105, pp. 606-613. [DOI: https://dx.doi.org/10.5935/abc.20150126] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26536980]

32. Abo, T.; Kawamura, T. Immunomodulation by the autonomic nervous system: therapeutic approach for cancer, collagen diseases, and inflammatory bowel diseases. Ther. Apher.; 2002; 6, pp. 348-357. [DOI: https://dx.doi.org/10.1046/j.1526-0968.2002.00452.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12423529]